David Pring-Mill

Tennis Champion Serena Williams Becomes GLP-1 Ambassador for Telehealth Company Ro

A telehealth company has announced a celebrity partnership to promote conversations about medical weight management. Ro, a direct-to-patient healthcare company, announced that 23-time Grand Slam champion Serena Williams has been using their platform to access GLP-1 medications and will serve […]

Tennis Champion Serena Williams Becomes GLP-1 Ambassador for Telehealth Company Ro Read More »

Codex Genetics Partners with Pacific Edge for Bladder Cancer Testing in Hong Kong

Bladder cancer’s high recurrence rate and lifelong monitoring requirements make it one of the most expensive cancers to manage globally. Hong Kong-based precision diagnostics company Codex Genetics recently announced an exclusive collaboration with Pacific Edge to bring non-invasive genomic urine

Codex Genetics Partners with Pacific Edge for Bladder Cancer Testing in Hong Kong Read More »

Children’s Hospital Colorado Updates Gait Lab with New Camera System

Children’s Hospital Colorado’s Center for Gait and Movement Analysis serves as the only accredited clinical gait and movement analysis lab in its region, evaluating hundreds of pediatric patients with movement disorders annually. The Aurora-based facility recently upgraded to Vicon’s Valkyrie

Children’s Hospital Colorado Updates Gait Lab with New Camera System Read More »

Hospitals Face Readiness Gap as CMS Glucose Reporting Mandate Approaches

As Medicare prepares to implement mandatory reporting requirements for blood glucose management in hospitals, healthcare facilities face a tight deadline to establish systems for tracking severe glycemic events. Glytec’s FDA-cleared Glucommander platform is among the technologies available to help hospitals

Hospitals Face Readiness Gap as CMS Glucose Reporting Mandate Approaches Read More »

TuHURA Biosciences Acquires VISTA-Inhibiting Antibody, Expanding Immuno-Oncology Pipeline

Tampa, Florida-based TuHURA Biosciences has completed its acquisition of Kineta, Inc., adding a Phase 2-ready VISTA-inhibiting monoclonal antibody to its pipeline of cancer immunotherapy treatments designed to overcome resistance mechanisms that limit current therapies. Key Points The acquisition positions TuHURA

TuHURA Biosciences Acquires VISTA-Inhibiting Antibody, Expanding Immuno-Oncology Pipeline Read More »